Evaxion A/S
Evaxion A/S (EVAX): 1 pipeline candidate · 1 clinical trial. Updated within the last hour.
BioSniper Score
3-factor signal · derived from public data
N/A
D/E 0.11 · 0% dilution
Lead: Phase 2
1 candidate
N/A
N/A
A transparent, data-derived signal for Evaxion A/Sacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$27.6M
Cash
$23.2M
Quarterly Burn
—
Runway
—
Revenue
—
Pipeline (1 candidate)
| Drug | Phase |
|---|---|
| evx-01 | Phase 2 |
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
12
Total value held
$601K
| Holder | Shares | Value |
|---|---|---|
| renaissance technologies llc | 39,225 | $146K |
| xtx topco ltd | 22,053 | $82K |
| rhumbline advisers | 21,659 | $81K |
| boothbay fund management, llc | 18,426 | $69K |
| citadel advisors llc | 17,773 | $66K |
| smartharvest portfolios, llc | 13,808 | $51K |
| wesbanco bank inc | 10,000 | $37K |
| northwestern mutual wealth management co | 8,000 | $30K |
| eversource wealth advisors, llc | 2,986 | $20K |
| gamma investing llc | 5,198 | $19K |
Showing top 10 of 12 institutional holders of Evaxion A/S. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Evaxion A/S's pipeline?
Evaxion A/S (EVAX) has 1 pipeline candidate tracked by BioSniper across SEC filings and clinical trial registrations.
What is Evaxion A/S's lead drug candidate?
Evaxion A/S's most advanced tracked candidate is evx-01 (Phase 2) for Melanoma Stage IV.
What is Evaxion A/S's market capitalization?
Evaxion A/S's market capitalization is approximately $27.6M.
Who is the CEO of Evaxion A/S?
Dr. Helen Katrina Tayton-Martin MBA, Ph.D. is the chief executive officer of Evaxion A/S (EVAX).
Get the full picture on Evaxion A/S
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.